156 related articles for article (PubMed ID: 31662561)
21. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
[TBL] [Abstract][Full Text] [Related]
22. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
William WN; Uyeki J; Johnson FM; Feng L; Peeples BO; Fossella FV; Karp DD; Blumenschein GR; Stewart DJ; Glisson BS
Cancer; 2010 May; 116(10):2409-15. PubMed ID: 20225329
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as
Second-line Treatment for Small Cell Lung Cancer].
Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
[TBL] [Abstract][Full Text] [Related]
24. Prognosis of small-cell lung cancer since the introduction of amrubicin.
Suzuki H; Hirashima T; Kobayashi M; Sasada S; Okamoto N; Tamiya M; Matsuura Y; Morishita N; Uehara N; Matsui K; Kawase I
Med Oncol; 2011 Dec; 28(4):1430-5. PubMed ID: 20632217
[TBL] [Abstract][Full Text] [Related]
25. Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: a retrospective study of 300 patients.
Nagy-Mignotte H; Guillem P; Vignoud L; Coudurier M; Vesin A; Bonneterre V; Toffart AC; Sakhri L; Brambilla C; Brambilla E; Timsit JF; Moro-Sibilot D;
Lung Cancer; 2012 Oct; 78(1):112-20. PubMed ID: 22795703
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
Sekine I; Harada H; Yamamoto N; Wakabayashi M; Murakami H; Goto K; Nogami N; Seto T; Oshita F; Okamoto H; Tanaka H; Tamura T; Ishikura S; Ohe Y
Lung Cancer; 2017 Jun; 108():232-237. PubMed ID: 28625642
[TBL] [Abstract][Full Text] [Related]
27. Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
Morise M; Niho S; Umemura S; Matsumoto S; Yoh K; Goto K; Ohmatsu H; Ohe Y
Jpn J Clin Oncol; 2014 Sep; 44(9):846-51. PubMed ID: 25057092
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of amrubicin and fixed dose of irinotecan (CPT-11) in relapsed small cell lung cancer: Japan multinational trial organization LC0303.
Kawahara M; Kubo A; Komuta K; Fujita Y; Sasaki Y; Fukushima M; Daimon T; Furuse K; Mishima M; Mio T
J Thorac Oncol; 2012 Dec; 7(12):1845-1849. PubMed ID: 22139390
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second-line chemotherapy in patients with small cell lung cancer.
Sekikawa M; Murakami H; Morita M; Doshita K; Miura K; Kodama H; Morikawa N; Iida Y; Mamesaya N; Kobayashi H; Ko R; Wakuda K; Ono A; Kenmotsu H; Naito T; Chiba H; Takahashi T
Thorac Cancer; 2023 Dec; 14(35):3475-3482. PubMed ID: 37873674
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
Kobayashi M; Matsui K; Iwamoto Y; Ebi N; Oizumi S; Takeda K; Sawa T; Shibata K; Saka H; Imamura F; Seki N; Saito H; Goto I; Nakagawa K;
J Thorac Oncol; 2010 Jul; 5(7):1075-80. PubMed ID: 20479694
[TBL] [Abstract][Full Text] [Related]
31. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
[No Abstract] [Full Text] [Related]
32. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).
Murakami H; Yamamoto N; Shibata T; Takeda K; Ichinose Y; Ohe Y; Yamamoto N; Takeda Y; Kudoh S; Atagi S; Satouchi M; Kiura K; Nogami N; Endo M; Watanabe H; Tamura T
Lung Cancer; 2014 Apr; 84(1):67-72. PubMed ID: 24530204
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases.
Mizugaki H; Fujiwara Y; Yamamoto N; Yagishita S; Kitazono S; Tanaka A; Horinouchi H; Kanda S; Nokihara H; Tsuta K; Asamura H; Tamura T
Jpn J Clin Oncol; 2014 Sep; 44(9):835-40. PubMed ID: 25097183
[TBL] [Abstract][Full Text] [Related]
34. Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy.
Arnold SM; Chansky K; Baggstrom MQ; Thompson MA; Sanborn RE; Villano JL; Waqar SN; Hamm J; Leggas M; Willis M; Rosales J; Crowley JJ
Clin Lung Cancer; 2020 Jul; 21(4):357-364.e7. PubMed ID: 32173247
[TBL] [Abstract][Full Text] [Related]
35. Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).
Uematsu S; Kitazono S; Tanaka H; Saito R; Kawashima Y; Ohyanagi F; Tozuka T; Ryosuke T; Sakatani T; Horiike A; Yoshizawa T; Saiki M; Tambo Y; Koyama J; Kanazu M; Kudo K; Tsuchiya-Kawano Y; Yanagitani N; Nishio M
Thorac Cancer; 2023 Jan; 14(2):168-176. PubMed ID: 36408699
[TBL] [Abstract][Full Text] [Related]
36. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.
Zhou K; Wen F; Zhang P; Zhou J; Zheng H; Sun L; Li Q
Clin Transl Oncol; 2018 Jun; 20(6):768-774. PubMed ID: 29098555
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group.
Mountzios G; Emmanouilidis C; Vardakis N; Kontopodis E; Hatzidaki D; Popis E; Karachaliou N; Kotsakis A; Agelidou M; Georgoulias V
Lung Cancer; 2012 Jul; 77(1):146-50. PubMed ID: 22418242
[TBL] [Abstract][Full Text] [Related]
39. A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.
Sekine I; Okamoto H; Horai T; Nakagawa K; Ohmatsu H; Yokoyama A; Katakami N; Shibuya M; Saijo N; Fukuoka M
Clin Lung Cancer; 2014 Mar; 15(2):96-102. PubMed ID: 24361248
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease.
Yoshida T; Yoh K; Goto K; Niho S; Umemura S; Ohmatsu H; Ohe Y
Anticancer Res; 2013 Mar; 33(3):1175-9. PubMed ID: 23482799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]